3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
NET
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
4
Thyroid Cancer, Papillary
1
Sarcoma
1
Salivary Gland Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neuroendocrine Tumors
1
Melanoma
1
Lymphoma, Large-Cell, Anaplastic
1
Head and Neck Neoplasms
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Renal Cell
1
Breast Neoplasms
1
Brain Neoplasms
1
Interventions
Nivolumab
21
pembrolizumab
19
Ipilimumab
14
Specimen Handling
12
Magnetic Resonance Spectroscopy
7
Opdualag
6
CTLA-4 Antigen
6
relatlimab
5
binimetinib
5
trametinib
4
Paclitaxel
4
dabrafenib
3
Taxes
3
Standard of Care
3
Pemetrexed
3
Introns
3
Interferon alpha-2
3
Gemcitabine
3
Carboplatin
3
Blood Specimen Collection
3
ulixertinib
2
sargramostim
2
lifileucel
2
lenvatinib
2
fludarabine phosphate
2
fludarabine
2
encorafenib
2
capivasertib
2
cabozantinib
2
atezolizumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Melanoma
×
entrectinib
×
30 days
×
Clear all
NCT02568267
2026-05-27
STARTRK-2
Hoffmann-La Roche
Phase 2
Active not recruiting
534 enrolled
1 FDA